DFFN VS MRK Stock Comparison

Performance

DFFN
10/100

DFFN returned -61.80% in the last 12 months. Based on SPY's performance of -8.71%, its performance is below average giving it a score of 10 of 100.

MRK
100/100

MRK returned 1.78% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

DFFN
75/100

1 analysts offer 12-month price targets for DFFN. Together, they have an average target of 0, the most optimistic target put DFFN at 0 within 12-months and the most pessimistic has DFFN at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

MRK
68/100

21 analysts offer 12-month price targets for MRK. Together, they have an average target of 113.88, the most optimistic target put MRK at 294 within 12-months and the most pessimistic has MRK at 80.

Technicals

DFFN
14/100

DFFN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

MRK
10/100

MRK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

DFFN
10/100

DFFN has missed earnings 7 times in the last 20 quarters.

MRK
53/100

MRK has missed earnings 3 times in the last 20 quarters.

Profit

DFFN
10/100

Out of the last 20 quarters, DFFN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

MRK
66/100

Out of the last 20 quarters, MRK has had 17 profitable quarters and has increased their profits year over year on 7 of them.

Volatility

DFFN
48/100

DFFN has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

MRK
52/100

MRK has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Dividend

DFFN

"Dividend" not found for DFFN

MRK
100/100

MRK's most recent dividend was $0.47 per share, based on a share price of $101.35. It was a payout ratio of 69.90% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

DIFFUSION PHARMACEUTICALS INC Summary

Nasdaq / DFFN

Healthcare

Biotechnology

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Merck & Co., Inc. Summary

New York Stock Exchange / MRK

Healthcare

Drug Manufacturers - General

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Power up your portfolio